Our Mission
improve immunological safety and efficacy of vaccines, drugs, and immune therapies by automating precise analysis of T-cell responses
Unmatched Efficiency for Immune Therapy Developers
100XBIO is a pioneering biotech hardware startup based in Boston, Massachusetts, founded in 2023.
​
Our technology significantly boosts the efficiency of clinical trials for therapeutic cancer vaccines by allowing the enrollment of more participants and rapidly validating numerous neoantigen targets for personalized cancer treatments.
Our solutions are designed for researchers and scientists in the biotech industry who are focused on developing cutting-edge cancer therapies and require precise, reliable data to drive their innovations forward.
Our Team
Led by a team of seasoned experts, including our CEO and founder Sergei Pustylnikov, we provide valuable insights and analyses that drive the biotech industry forward.
Core Team
Advisors
Askar K., PhD.
Business Advisor, 2x CEO,
VC management
Sofya Leyn, Ph.D
Co-founder, Data analysis, Sequencing
Andrei Afanasiev
VC partner, 2x CEO, VC Funding Advising
PhD, Biotech executive, Product Development